Biom’up SA, specialising in surgical hemostasis, appointed Patrice Ferrand as their new CEO. Ferrand replaces Jan Ohrstrom, who was appointed CEO since May and remains Chairman of the Board.
ADVERTISEMENT
H.E.L. Group Ltd has a new CEO: The global manufacturer of laboratory tools for process optimisation, safety and scale-up announced the appointment of Louise Madden as Chief Executive Officer.
Edwin Klumper of Lytix Biopharma has stepped down from his role as CEO. The board has decided to promote Head of R&D Øystein Rekdal to the position of CEO.
British cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiys executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.
The Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.
PDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.
Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Iteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.
Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the companys Interim Chief Financial Officer since April 26, 2019.
Pieris Pharmaceuticals, Inc. today announced that Maya R. Said, Sc.D., has joined the Companys Board of Directors.